ginsenoside Rg3

from Red ginseng; inhibits lung metastasis of tumor cells; structure given in first source

Also Known As:

20(R)-ginsenoside Rg(3); 20(S)-ginsenoside Rg(3); 20s-ginsenoside rg3; 3-O-beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranosyldammar-24-ene-3beta,12beta,20s-triol; beta-D-glucopyranoside, (3beta,12beta)-12,20-dihydroxydammar-24-en-3-yl 2-O-beta-D-glucopyranosyl-; ginsenoside 20-rg3; ginsenoside Rg(3); ginsenoside rg3, (+)-; ginsenoside rg3, (s)-; s-ginsenoside rg3

Networked: 292 relevant articles (23 outcomes, 75 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Yan, Qiu: 6 articles (12/2019 - 01/2014)
2.	He, Tong-Chuan: 6 articles (07/2013 - 12/2006)
3.	Wang, Chong-Zhi: 6 articles (07/2013 - 12/2006)
4.	Yuan, Chun-Su: 6 articles (07/2013 - 12/2006)
5.	Fu, Li: 5 articles (10/2021 - 11/2017)
6.	Du, Wei: 5 articles (07/2013 - 05/2008)
7.	Zhu, Yan: 4 articles (03/2022 - 01/2017)
8.	Li, Wei: 4 articles (03/2021 - 01/2018)
9.	Li, Xiao: 4 articles (01/2021 - 05/2012)
10.	Liu, Jiwei: 4 articles (12/2019 - 01/2016)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2022 - "Efficacy of ginsenoside Rg3 nanoparticles against Ehrlich solid tumor growth in mice." 06/01/2022 - "The current study aimed to fabricate ginsenoside Rg3 nanoparticles (Rg3-NPs) and evaluate their antitumor effect against Ehrlich solid tumors (EST) in mice. " 01/01/2020 - "An increasing number of studies have demonstrated that ginsenoside Rg3 (Rg3), which is extracted from the roots of the traditional Chinese herb Panax ginseng, plays a tumor suppression role in various malignant tumors. " 08/01/2019 - "Ginsenoside Rg3 (Rg3) has two epimers, 20(S)-ginsenoside Rg3 (SRg3) and 20(R)-ginsenoside Rg3 (RRg3), and while Rg3 itself has been reported to have anti-cancer properties, few studies have been reported on the anti-cancer effects of the different epimers. " 01/01/2016 - "However, there is no study on pharmacokinetics (PKs) of ginsenoside Rg3 and its main metabolite after oral ginsenoside Rg3 in tumor-bearing plasma. "
2.	Lewis Lung Carcinoma 07/23/2009 - "The present study was designed to evaluate the efficacy of low-dose gemcitabine combined with ginsenoside Rg3 on angiogenesis and growth of established Lewis lung carcinoma in mice. " 04/14/2006 - "In the present study, we investigated the efficacy of the combination of low-dose cyclophosphamide and ginsenoside Rg3 for the antiangiogenic effect on Lewis lung carcinoma. " 04/20/2006 - "The aim of this study is to investigate the inhibitory effects of administration of low-dose gemcitabine combined with ginsenoside Rg3 on angiogenesis of mouse Lewis lung carcinoma and the influence of administration on quality of life of mouse. " 08/01/2005 - "[Experimental study on anti-angiogenesis in mice with Lewis lung carcinoma by low-dose of cyclophosphamide combined with ginsenoside Rg3]." 07/23/2009 - "C57L/6 mice implanted with Lewis lung carcinoma were randomized into the control, ginsenoside Rg3, gemcitabine and combination group. "
3.	Inflammation (Inflammations) 11/01/2021 - "Ginsenoside Rg3 ameliorates allergic airway inflammation and oxidative stress in mice." 11/01/2021 - "Ginsenoside Rg3 treatment significantly reduced eosinophil infiltration, oxidative responses, airway inflammation, and AHR in the lungs of asthmatic mice. " 10/01/2020 - "A Critical Regulation of Th17 Cell Responses and Autoimmune Neuro-Inflammation by Ginsenoside Rg3." 01/01/2020 - "Compelling evidence has demonstrated that ginsenoside Rg3 is capable of inhibiting inflammation. " 01/01/2018 - "However, the specific molecular mechanism of the effects of ginsenoside Rg3 on inflammation has rarely been reported. "
4.	Neoplasm Metastasis (Metastasis) 06/01/2019 - "When ovarian cells were treated with ginsenoside Rg3, cell apoptosis was observed to be promoted, while cell metastasis and invasion were inhibited at 48 h. " 12/28/2015 - "Anti-Metastasis Effects of Ginsenoside Rg3 in B16F10 Cells." 01/01/2020 - "In conclusion, nanoparticle conjugation of ginsenoside Rg3 inhibits HCC development and metastasis via the remodeling of unbalanced gut microbiota and metabolism in vivo, providing an antitumor therapy strategy." 08/05/2008 - "The present study was undertaken to investigate the effect of ginsenoside Rg3 on human ovarian cancer metastasis and the possible mechanism. " 01/01/2020 - "Nanoparticle Conjugation of Ginsenoside Rg3 Inhibits Hepatocellular Carcinoma Development and Metastasis."
5.	Carcinogenesis 12/01/2019 - "Taken together, these results show that ginsenoside Rg3 upregulate VRK1 expression and P53BP1 foci formation in response to DNA damage thereby inhibiting the tumorigenesis and viability of cancer cells. " 01/01/2023 - "The preventive role of the red gingeng ginsenoside Rg3 in the treatment of lung tumorigenesis induced by benzo(a)pyrene." 01/01/2018 - "Ginsenoside Rg3, a saponin extracted from ginseng, shows cytotoxicity against a variety of cancer cells through suppression of pathways linked to oncogenesis, including cell survival, proliferation, invasion, and angiogenesis. " 03/01/2023 - "Ginsenoside Rg3 may benefit NSCLC patients with COVID-19 by regulating signaling pathways primarily involved in anti-inflammation, immunomodulation, cell cycle, cell fate, carcinogenesis, and hemodynamics. " 11/01/1997 - "Although administration of a higher dose of ginsenoside Rg3 with bombesin had little or no effect on the enhancement of intestinal carcinogenesis by bombesin, the location, histologic type, depth of involvement, infiltrating growth pattern, labeling and apoptotic indices and tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis. "

Related Drugs and Biologics

1.	Gemcitabine
2.	Cyclophosphamide (Cytoxan)
3.	Cisplatin (Platino)
4.	Curcumin
5.	Glucose (Dextrose)
6.	Vascular Endothelial Growth Factor Receptor-3 (Flt 4)
7.	Rotenone
8.	Sirtuin 1
9.	Lipopolysaccharides
10.	Resveratrol

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Chinese Traditional Medicine (Traditional Chinese Medicine)
3.	Radiotherapy
4.	Oral Administration
5.	Therapeutics